- COMMENT
First, do no harm: a global perspective on diversity and inclusion in clinical trials
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41573-024-00078-4
References
Schwartz, A. L., Alsan, M., Morris, A. A. & Halpern, S. D. Why diverse clinical trial participation matters. N. Engl. J. Med. 388, 1252–1254 (2023).
Peters, U. et al. Considerations for embedding inclusive research principles in the design and execution of clinical trials. Ther. Innov. Regul. Sci. 57, 186–195 (2023).
Castellon-Lopez, Y. et al. A community-partnered approach for diversity in COVID-19 vaccine clinical trials. J. Clin. Transl Sci. 7, e23 (2022).
Ioannidis, J. P. A., Powe, N. R. & Yancy, C. Recalibrating the use of race in medical research. JAMA 325, 623–624 (2021).
National Academies of Sciences, Engineering, and Medicine. Using Population Descriptors in Genetics and Genomics Research: A New Framework for an Evolving Field (The National Academies Press, 2023).
Competing Interests
The authors declare no competing interests.